



OPEN ACCESS

*CORRESPONDENCE

EBM Production Office,
✉ production@ebm-journal.org,

RECEIVED 26 December 2025

REVISED 26 December 2025

ACCEPTED 13 February 2026

PUBLISHED 03 August 2026

CITATION

EBM Production Office (2026)
Correction: Protective effects of
berberine-loaded chitosan/solid lipid
nanoparticles in streptozotocin-
induced gestational diabetes
mellitus rats.

Exp. Biol. Med. 251:10958.

doi: 10.3389/ebm.2026.10958

COPYRIGHT

© 2026 EBM Production Office. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Correction: Protective effects of berberine-loaded chitosan/solid lipid nanoparticles in streptozotocin-induced gestational diabetes mellitus rats

EBM Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

berberine, chitosan, gestational diabetes mellitus, rat, solid lipid nanoparticle

A Correction on

[Protective effects of berberine-loaded chitosan/solid lipid nanoparticles
in streptozotocin-induced gestational diabetes mellitus rats](#)

by Liu Y, Hussain SA and Yue H (2025). *Exp. Biol. Med.* 250:10749. doi: [10.3389/ebm.2025.10749](#)

In the main article, the name of the ethics committee was erroneously given as “the Institutional Ethics Committee and Research Advisory Committee of the King Saud University, Saudi Arabia” and the location that the rats were obtained from was erroneously given as “the laboratory animal research center of the College of Science, King Saud University, Saudi Arabia”.

A correction has been made to the **Material and Methods** section, subsection ‘Gestational rats’. The correct paragraph appears below:

“Forty-nine female (180 ± 10 g) and seven male (230 ± 10 g) Wistar-Albino rats (8–10 weeks old) were obtained from Takassusi BioMedical, Riyadh, Saudi Arabia. All animal experiments were performed in full accordance with the Animal Welfare instructions and approved by Zhinanzhen Biology Ethics Committee, [No.: A2025000127.]”

The original version of this article has been updated.